Search the Newsreel

Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock

Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness sold 16,167 shares of the company's stock for approximately $1.78 million, reducing his stake by over 80%. This transaction occurred as the company's shares fell 3.0% to $108.49, following a quarterly earnings report that missed EPS estimates but …

Simon Read Sells 2,777 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics Director Simon Read sold 2,777 shares of the company's stock for over $304,000, reducing his stake by 50%. This transaction occurred as DNTH shares experienced a 3.0% decline following a quarterly earnings report that missed EPS estimates, despite revenue exceeding expectations. Analysts …

LightInTheBox (LITB) CEO He Jian lifts holding to 24.1% after US$1.09M PIPE

LightInTheBox Holding Co., Ltd. CEO and chairman He Jian has increased his beneficial ownership to 24.1% of the company's outstanding ordinary shares following a US$1.09 million Private Investment in Public Equity (PIPE). This investment was made through Conner Growth Holding Limited, an entity wholly …

Why Is Panthera Resources (LSE:PAT) Back in Gold Focus?

Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH

Pacer Advisors Inc. significantly reduced its stake in Lantheus Holdings, Inc. by 97.0% in the first quarter, selling 247,589 shares and retaining 7,704 shares valued at $584,000. Despite this, other institutional investors have recently modified their holdings, and 99.06% of the stock is still …

Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?

Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) for US$102.50 in cash per share plus contingent value rights up to US$12.00 per share, with the deal expected to close in the first half of 2027. The article discusses whether the remaining upside …

DNTH insider Adam M. Veness plans Rule 144 sale of 16,167 shares

Adam M. Veness, an insider at Dianthus Therapeutics, Inc. (DNTH), has filed a Rule 144 notice to sell 16,167 common shares valued at $1,760,909.64. The transaction, scheduled for August 10, 2026, involves an exercise of stock options for cash on the same date and …

LightInTheBox (NYSE: LITB) raises $5.49M in PIPE share placement

LightInTheBox Holding Co., Ltd. (NYSE: LITB) has completed a private placement (PIPE), raising approximately $5.49 million in gross proceeds. The company issued 21,397,409 ordinary shares at $0.2566667 per share, equivalent to $3.08 per American Depositary Share, to institutional investors. LightInTheBox has also received NYSE …

NORTHROP GRUMMAN AKTIE: AI-Analysen, Prognose & Kursziel

Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH

Empowered Funds LLC initiated a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by purchasing 11,979 shares valued at approximately $909,000. This comes as Lantheus exceeded quarterly earnings expectations, reporting $1.55 EPS against a $1.30 consensus, though analyst sentiment has softened with several downgrades to …

Assenagon Asset Management S.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

HC Wainwright Issues Optimistic Outlook for DNTH Earnings

Anthem Biosciences Shares Rise 2.20% to Rs 859.50

LightInTheBox Holding Co., Ltd. Sponsored ADR Revenue Breakdown – GETTEX:L4X

LightInTheBox Holding Co., Ltd. (GETTEX:L4X) generated 190.97 million EUR in revenue last year, primarily from its Product Sales segment, which accounted for 525.53 million EUR. The company's largest regional contribution came from Europe, bringing in 266.97 million EUR. These figures represent a shift from …

LightInTheBox Holding Co., Ltd. announced that it has received $5.492009 million in funding

LightInTheBox Holding Co., Ltd. has announced the receipt of $5.492009 million in funding, closing the transaction on August 10, 2026. This follows an earlier announcement on July 9, 2026, where the company anticipated receiving this funding. The company, known for its Ador.com apparel brand, …

Barinthus Biotherapeutics plc Revenue Breakdown – NASDAQ:BRNS

California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

The California State Teachers Retirement System significantly increased its stake in Dianthus Therapeutics (DNTH) by 155.5% in the first quarter, now owning 40,584 shares valued at $3.4 million. Despite this institutional confidence and generally positive analyst ratings, the company faces risks including ongoing losses, …

Dianthus Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Dianthus Therapeutics Inc is projected to report a loss of 86 cents per share. This information comes from an earnings preview provided by Reuters, accessible through TradingView News. The full article and more content from various news sources are available with an unlimited access …

Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.'s 2nd Largest Position

Reinhart Partners LLC. has increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2%, making it their second-largest holding and comprising 4.1% of their portfolio. Despite this, analyst sentiment has softened, leading to several downgrades to "Hold" and a consensus price target of $108.11. …

Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com

Marino Garcia, CEO of Dianthus Therapeutics (NASDAQ:DNTH), sold 166,000 shares totaling approximately $17.95 million on August 7, 2026, following the exercise of stock options. The sale occurred near the stock's 52-week high after a significant 481% return, aligning with an analyst valuation suggesting the …

Analysts Have Lowered Expectations For Synthomer plc (LON:SYNT) After Its Latest Results

Lantheus (LNTH) Stock Shrugs Off Solid Profit As Margin Questions Linger

Lantheus Holdings (LNTH) stock saw a minimal price change despite solid Q2 earnings, with revenue meeting expectations and EPS remaining flat year-over-year. Investors are weighing the company's strong trailing P/E against questions about future growth pillars like Alzheimer’s diagnostics and operating leverage, especially after …

Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 7, 2026)

This article reports on Dianthus Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of 40,000 shares of common stock with an aggregate market value of $4,396,800.00, resulting from the exercise of stock options. The filing has …

Synthomer plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:SYHMY) 2026-08-07

Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics CEO Marino Garcia sold 166,000 shares of the company's stock for approximately $17.95 million, reducing his direct ownership by 71.77%. The sale occurred on August 7th, with shares trading at $108.11 on average. Despite missing recent earnings estimates, the company's stock is …

Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 million

Dianthus Therapeutics CEO and President Marino Garcia exercised options for 166,000 shares at $8.44 each, increasing his direct holdings. Subsequently, he sold these 166,000 shares at prices ranging from $107.49 to $110.76, reducing his direct common stock holdings to 65,292 shares. The total value …

Northrop Grumman Corp (NOC) Aktienanalyse & Prognose

Dianthus Therapeutics (DNTH): T. Rowe Price reports 7.1% stake in common stock

T. Rowe Price Investment Management, Inc. has reported a 7.1% stake in Dianthus Therapeutics Inc.'s common stock, totaling 3,888,456 shares. The investment firm holds sole voting power over 3,884,903 shares and sole dispositive power over all 3,888,456 shares. Despite this, T. Rowe Price explicitly …

DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125

Raymond James has increased its target price for Dianthus Therapeutics Inc. to $131 from $125. The article, sourced from Reuters, indicates this change in financial outlook for the company. The content primarily highlights this price target adjustment.

Barinthus Biotherapeutics (Nasdaq: BRNS) details Q2 loss, cash and Clywedog merger plan

Barinthus Biotherapeutics (BRNS) reported a Q2 2026 net loss of $10.6 million and a six-month net loss of $16.1 million, improvements over the prior year due to reduced R&D and administrative expenses. The company holds $59.6 million in cash, expected to fund operations for …

TwentyFour Select Monthly Income Fund Raises £2.6m Through New Share Issue

Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential additional payments of up to $12.00 per share via Contingent …

Why Enthusiast Gaming Holdings Inc stock plummeted yesterday

Synthomer (LON:SYNT) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Panther Metals Sells Northern Territory Lease to Fund WA Focus